Non-HDL Cholesterol and LDL Cholesterol as Main Risk Factors for Coronary Heart Disease: Meta-Analysis
DOI:
https://doi.org/10.24293/ijcpml.v28i3.2006Keywords:
LDL cholesterol, non-HDL cholesterol, coronary heart diseaseAbstract
Coronary heart disease is a highly frequent illness in both developed and developing nations. Non-HDL cholesterol (n-HDL-c) and LDL cholesterol (LDL-c) stages are biomarkers that doctors frequently utilize to assess the risk of Coronary Heart Disease (CHD). This study was a systematic review and meta-analysis to assess the association between n-HDL-c and LDL-c as major risk factors for CHD. Cochrane, PubMed, and Science Direct searches were conducted using the keywords "LDL cholesterol," "non-HDL cholesterol," and "coronary heart disease." Any research that describes the analysis of LDL-c and n-HDL-c as key risk factors for CHD and all studies involving patients diagnosed with CHD are included in the literature. A total of seven papers were involved in the qualitative analysis (systematic review), while five studies were included in the quantitative analysis (meta-analysis). The English-language research includes two RCTs, four case-control studies, and one cohort study, with a total of 68,713 individuals. LDL-c parameters were obtained (MD = 8.45; 95 percent CI = 7.03-9.87 p=0.001) and n-HDLc (p=0.001) (MD = 35.57; 95 percent CI = 33.27-37.88). n-HDL-c may be a more significant parameter of CHD risk because it has a higher MD value.
Downloads
References
Shahjehan RD, Bhutta BS. Coronary artery disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022; 15(1): 150-9.
Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med, 2016; 4(13): 1-12.
Hussain MA, Mamun A Al, Peters SAE, Woodward M, Huxley RR. The burden of cardiovascular disease
attributable to major modifiable risk factors in Indonesia. J Epidemiol, 2016; 26(10): 515-21.
Maharani A, Sujarwoto, Praveen D, Oceandy D, Tampubolon G, Patel A. Cardiovascular disease risk
factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: The SMARThealth extend study. PLos One, 2019; 14(4): 1-13.
The George Institute for Global Health. Reducing the burden of cardiovascular disease in Indonesia the George Institute for Global Health. Cardiovascular Division; Health Services Research Centre, 2017;
-38.
Shoar S, Ikram W, Shah AA, Farooq N, Gouni S, et al. Non-high-density lipoprotein (non-HDL) cholesterol in adolescence as a predictor of atherosclerotic cardiovascular diseases in adulthood. Rev Cardiovasc Med, 2021; 22(2): 295-9.
Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL
cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet, 2016; 380(9841): 581-90.
You J, Wang Z, Lu G, Chen Z. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and the risk of coronary artery disease. Biomed Res Int, 2020; 2020.
Zeng L, Ye Z, Li Y, Zhou Y, Shi Q, et al. Different lipid parameters in predicting clinical outcomes in Chinese Statin-naí¯ve patients after coronary stent implantation. Front Cardiovasc Med, 2021; 8: 1-7.
Koba S, Takao T, Shimizu F, Ogawa M, Ishii Y, et al. Comparison of plasma levels of different species of trans fatty acids in Japanese male patients with acute coronary syndrome ver sus healthy men.
Atherosclerosis, 2019; 284: 173-80.
Shabana, Shahid SU, Sarwar S. The abnormal lipid profile in obesity and Coronary Heart Disease (CHD) in Pakistani subjects. Lipids Health Dis, 2020; 19(1): 1-7.
Ihm SH, Chung WB, Lee JM, Hwang BH, Yoo KD, et al. Efficacy and tolerability of Pitavastatin versus
Pitavastatin/Fenofibrate in high-risk Korean patients with mixed dyslipidemia: A multicenter, randomized, double-blinded, parallel, therapeutic confirmatory clinical trial. Clinical Therapeutics, 2020; 42(10): 2021-2035.e3. Available from: https://doi.org/10.1016/j.clinthera.2020.08.002 (accessed February
, 2022).
Arca M, Ansell D, Averna M, Fanelli F, Gorcyca K, et al. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018; 271: 120-7.
Teramoto T, Daida H, Ikewaki K, Arai H, Maeda Y, et al. Lipid-modifying efficacy and tolerability of
anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis
[Internet]. 2017; 261: 69-77. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2017.03.009 (accessed February 16, 2022).
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/
ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the
American College of Cardiology/American Heart Association task force on clinical practice guidelines.
Journal of the American College of Cardiology, 2019; 73(24), e285-e350. Available from : https://doi.org/
1016/j.jacc.2018.11.003 (accessed June 7, 2022).
Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, et al. Association of triglyceride lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA-J
Am Med Assoc, 2019; 321(4): 364-73.
Sulistian WD, Fuadi MR, Edijanto SP, Yusuf M. Effect of dyslipidemia therapy on creatinine kinase activity level in patients with heart disease. Indones J Clin Pathol Med Lab, 2021; 27(2): 132-7.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
